CDK4/6 inhibitor trials for Breast cancer

All CDK4/6 inhibitor trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying CDK4/6 inhibitor for Breast cancer

• A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
  NCT07666555 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
  NCT07180056 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
  NCT07117630 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
  NCT06447623 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
  NCT05795335 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
  NCT07180160 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study CDK4/6 inhibitor for Breast cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.